Table 1. Baseline Patient Characteristics and Perioperative Data.
Characteristics | Participants, No. (%) (Nā=ā201) |
---|---|
Age, median (IQR), y | 65 (57-72) |
Sex | |
Female | 85 (42.3) |
Male | 116 (57.7) |
Location of primary tumor (n = 199)a | |
Ascending colon | 40 (20.1) |
Transverse colon | 6 (3.0) |
Descending colon | 9 (4.5) |
Sigmoid | 72 (36.2) |
Rectum | 72 (36.2) |
T stage | |
T1 | 8 (4.0) |
T2 | 23 (11.6) |
T3 | 135 (67.8) |
T4 | 33 (16.6) |
N stage | |
N0 | 63 (31.8) |
N1 | 90 (45.5) |
N2 | 45 (22.7) |
M stage | |
M0 | 99 (49.0) |
M1 | 102 (51.0) |
Serum carcinoembryonic antigen, ng/mL, median (IQR) | 5.9 (2.7-15.0) |
No. of suspected CRLM lesions, mean (SD) | 2.17 (2.30) |
Size of largest lesion, mm, median (IQR) | 22 (14-35) |
Neoadjuvant chemotherapy | 58 (28.9) |
Surgery characteristics, median (IQR) | |
Operation time, min | 157 (30-450) |
Estimated blood loss, mL | 150 (50-350) |
Hospital stay, d | 3 (2-4) |
Clavien-Dindo classificationb | |
No complication | 169 (84.1) |
Low | 15 (7.5) |
High | 11 (5.5) |
Missing | 6 (3.0) |
Abbreviation: CRLM, colorectal liver metastases.
SI conversion: To convert carcinoembryonic antigen to micrograms per liter, multiply by 1.0.
Data from 2 patients were missing because they were referred from a center outside of the Netherlands, and both patients were unaware of the location of their primary tumor.
Classifications range from 0 to 5, with 3 to 5 indicting more severe postoperative complications.